Antineoplastic agents 460. Synthesis of combretastatin A-2 prodrugs

Anti-Cancer Drug Design

Volumn 16, Issue 4-5, 2001, Pages 185-193

  Pettit, George R ^a   Moser, Bryan R ^a   Boyd, Michael R ^b   Schmidt, Jean M ^a   Pettit, Robin K ^a   Chapuis, Jean Charles ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antineoplastic activity; Combretastatin A 2 prodrug; Phosphate esters

Indexed keywords

AMMONIA; ANTINEOPLASTIC AGENT; BENZYL DERIVATIVE; BROMOTRIMETHYLSILANE; COMBRETASTATIN; COMBRETASTATIN A2; DIBENZYLCHLOROPHOSPHITE; ESTER; METAL ION; METHOXIDE SODIUM; OXIDE; PHOSPHATE; PHOSPHITE; PHOSPHORIC ACID; PRODRUG; SILANE DERIVATIVE; SODIUM DERIVATIVE; STILBENE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CHEMICAL REACTION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; PHOSPHORYLATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BACTERIA; BIBENZYLS; DRUG DESIGN; HUMANS; INDICATOR DILUTION TECHNIQUES; INDICATORS AND REAGENTS; ISOMERISM; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; PHOSPHATES; PRODRUGS; SOLUBILITY; STILBENES; TUMOR CELLS, CULTURED;

EID: 0035437387     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Adams D.J., Knick V.C. (1995) p-Glycoprotein resistance to 5′-nor-anhydro vinblastine (Navelbine®). Investigational New Drugs, 13, 13.
2. Boyd M.R. (1997) The NCI in vitro anticancer drug discovery screen: Concept, implementation and operation 1985-1995. In Cancer Drug Discovery and Development, Vol. 2. Drug Development: Preclinical Screening, Clinical Trial and Approval. Teicher B.A. (ed.), p. 23. Totowa, NJ: Humana Press.
3. Boyd M.R., Paull K.D. (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Development Research, 34, 91.
4. Bundgaard H. (1991) In A Textbook of Drug Design and Drug Development. Krogsgaard-Larson P., Bundgaard H. (eds), p. 148. Harwood Academic Publishers.
5. Chao H.G., Bernatowicz M.S., Klimas C.E., Matsueda G.R. (1993) N,N-Diisopropyl-bis[2-(trimethylsilyl)ethyl]phosphoramidite. An attractive phosphitylating agent compatible with the Fmoc/t-butyl strategy for the synthesis of phosphotyrosine containing peptides. Tetrahedron Letters, 34, 3377.
6. Chen G.R., Ramachandran C., Krishan A. (1993) Thaliblastine, a plant alkaloid circumvents multidrug resistance by direct binding to p-glycoprotein. Cancer Research, 53, 2544.
7. Genne P., Duchamp O., Solary E., Magnette J., Belon J.P., Chauffert D. (1995) Cinchonine per os: Efficient circumvention of p-glycoprotein-mediated multidrug resistance. Anti-Cancer Drug Design, 10, 103.
8. Grosios K., Holwell S.E., McGown A.T., Pettit G.R., Bibby M.C. (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. British Journal of Cancer, 81, 1318.
9. Kang Y., Perry R.R. (1994) Effect of α-interferon on p-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Research, 54, 2952.
10. Lazar S., Guillaumet G. (1992) A selective removal of benzyl protecting groups in arylphosphate esters with bromotrimethylsilane. Synthetic Communications, 22, 923.
11. Lin C.M., Singh S.B., Chu P.S., Dempcy R.O., Schmidt J.M., Pettit G.R., Hamel E. (1988) Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study. Molecular Pharmacology, 34, 200.
12. Lin C.M., Ho H.H., Pettit G.R., Hamel E. (1989) Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry, 28, 6984.
13. National Committee for Clinical Laboratory Standards (1997a) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A4. Wayne, PA: NCCLS.
14. National Committee for Clinical Laboratory Standards (1997b) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A. Wayne, PA: NCCLS.
15. Pettit G.R., Lippert J.W. III (2000) Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anti-Cancer Drug Design, 15, 203.
16. Pettit G.R., Rhodes M.R. (1998) Antineoplastic agents 389. New synthesis of the combretastatin A-4 prodrug. Anti-Cancer Drug Design, 13, 183.
17. Pettit G.R., Singh S.B. (1987) Isolation, structure and synthesis of combretastatin A-2, A-3, and B-2. Canadian Journal of Chemistry, 65, 2390.
18. Pettit G.R., Cragg G.M., Herald D.L., Schmidt J.M., Lohavanuaya, P. (1982) Isolation and structure of combretastatin. Canadian Journal of Chemistry, 610, 1374.
19. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., Garcia-Kendall D. (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, 45, 209.
20. Pettit G.R., Temple C. Jr, Narayanan V.L., Varma R., Simpson M.J., Boyd M.R., Rener G.A., Bansal N. (1995a) Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anti-Cancer Drug Design, 10, 299.
21. Pettit G.R., Freeman S., Simpson M.J., Thompson M.S., Boyd M.R., Williams M.D., Pettit G.R. III, Doueek D.L. (1995b) Antineoplastic agents 320. Synthesis of a practical pancratistatin prodrug. Anti-Cancer Drug Design, 10, 243.
22. Pettit G.R., Singh S.B., Boyd M.R., Hamel E., Pettit R.K., Schmidt J.M., Hogan F. (1995c) Antineoplastic agents 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. Journal of Medicinal Chemistry, 38, 1666.
23. Pettit G.R., Rhodes M.R., Herald D.L., Chaplin D.J., Stratford M.R.L., Hamel E., Pettit R.K., Chapuis J.-C., Oliva D. (1998) Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anti-Cancer Drug Design, 13, 981.
24. Pettit G.R., Lippert J.W. III, Herald D.L., Hamel E., Pettit R.K. (2000) Antineoplastic agents 440. Asymmetric synthesis and evaluation of the combretastatin A-1 SAR probes (1S,2S)- and (1R,2R)-1,2-dihydroxy-1- (2′,3′-dihydroxy-4′-methoxyphenyl)-2- (3″,4″,5″-trimethoxyphenyl)ethane. Journal of Natural Products, 63, 969.
25. Reitz A.B., Nortey S.O., Jordan A.D., Mutter M.S. Jr, Maryanoff B.E. (1986) Dramatic concentration dependence of stereochemistry in the Wittig reaction. Examination of the lithium salt effect. Journal of Organic Chemistry, 51, 3302.
26. Remick S.C., Dowlati A., Robertson K., Spiro T., Connell C., Levitan N., Stratford M. (1999) Phase I pharmacokinetics study of single dose intravenous (IV) combretastatin A-4 prodrug (CA4P) in patients (pts) with advanced cancer. In Molecular Targets and Cancer Therapeutics Discovery, Development, and Clinical Validation, Proceedings of the 1999 AACR-NCIEORTC International Congress, Washington, DC, abstract no. 16, p. 4.
27. Rustin G.J.S., Galbraith S.M., Taylor N.J., Maxwell R., Tozer G., Baddeley H., Wilson I., Prise V. (1999) Combretastatin A-4 phosphate (CA4P) selectively targets vasculature in animal and human tumors. In Molecular Targets and Cancer Therapeutics Discovery, Development, and Clinical Validation, Proceedings of the 1999 AACR-NCI-EORTC International Congress, Washington, DC, abstract no. 14, p. 4.
28. Sato W., Fukazaqa N., Nakanishi O., Baba M., Suzuki T., Yano O., Naito M., Tsuruo T. (1995) Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemotherapy and Pharmacology, 35, 271.
29. Saulnier M.G., Langley D.R., Kadow J.F., Senter P.D., Knipe J.O., Tun M.M., Vyas D.M., Doyle T.W. (1994) Synthesis of etoposide phosphate, BMY-40481: A water soluble clinically active prodrug of etoposide. Bioorganic & Medicinal Chemistry Letters, 4, 2567.
30. Silverberg L.J., Dillon J.L., Vemishetti P. (1996) A simple, rapid, and efficient protocol for the selective phosphorylation of phenols with dibenzyl phosphate. Tetrahedron Letters, 37, 771.
31. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R.L., Dennis M.F., Chaplin D.J. (1999) Combretastatin A-4 phosphate as a tumor vascular targeting agent: Early effects in tumors and normal tissues. Cancer Research, 59, 1626.
32. Ueda Y., Mikkilineni A.B., Knipe J.O., Rose W.C., Casazza A.M., Vyas D.M. (1993) Novel water-soluble phosphate prodrugs of Taxol possessing in vivo antitumor activity. Bioorganic & Medicinal Chemistry Letters, 3, 1761.
33. Vyas D.M., Wong H., Corsswell A.R., Casazza A.M., Knipe J.O., Mamber S.W., Doyle T.W. (1993) Synthesis and antitumor evaluation of a water soluble Taxol phosphate. Bioorganic & Medicinal Chemistry Letters, 3, 1357.
34. Watanabe T., Naito M., Kokubu N., Tsuruo T. (1997) Regression of established tumors expressing p-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. Journal of the National Cancer Institute, 89, 512.
35. Williams A.B., Jacobs R.S. (1993) A marine animal product, patellamide D, reverses multidrug resistance in a human leukemic cell line. Cancer Letters, 71, 97.